Aldeyra Therapeutics, Inc. Logo

Aldeyra Therapeutics, Inc.

Biotech developing therapies for ocular and systemic immune-mediated inflammation.

ALDX | US

Overview

Corporate Details

ISIN(s):
US01438T1060
LEI:
Country:
United States of America
Address:
131 HARTWELL AVENUE, 2421 LEXINGTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing medicines to treat immune-mediated diseases. The company's portfolio of product candidates is designed to inhibit inflammatory cells associated with both ocular and systemic ailments, addressing unmet needs where existing treatments are insufficient. Through ongoing clinical trials, Aldeyra is advancing a pipeline of next-generation therapies with the objective of improving patient well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aldeyra Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aldeyra Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aldeyra Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany MYNZ
MAINZ BIOMED N.V. Logo
Develops molecular genetic diagnostic tests for early colorectal cancer detection in the US & Europe.
United States of America MYNZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.